HomeCompareWPDPF vs CL

WPDPF vs CL: Dividend Comparison 2026

WPDPF yields 6666666.67% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WPDPF wins by $8.25873857526507e+44M in total portfolio value
10 years
WPDPF
WPDPF
● Live price
6666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.25873857526507e+44M
Annual income
$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00
Full WPDPF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — WPDPF vs CL

📍 WPDPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWPDPFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WPDPF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WPDPF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WPDPF
Annual income on $10K today (after 15% tax)
$566,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, WPDPF beats the other by $701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WPDPF + CL for your $10,000?

WPDPF: 50%CL: 50%
100% CL50/50100% WPDPF
Portfolio after 10yr
$4.129369287632535e+44M
Annual income
$412,924,744,481,180,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

WPDPF
No analyst data
Altman Z
-107.3
Piotroski
0/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WPDPF buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWPDPFCL
Forward yield6666666.67%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$8.25873857526507e+44M$41.0K
Annual income after 10y$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$5,451.69
Total dividends collected$8.258722632802889e+44M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: WPDPF vs CL ($10,000, DRIP)

YearWPDPF PortfolioWPDPF Income/yrCL PortfolioCL Income/yrGap
1← crossover$666,677,367$666,666,666.67$11,014$313.84+$666.67MWPDPF
2$41,538,243,978,220$41,537,530,633,437.17$12,200$415.44+$41538243.97MWPDPF
3$2,418,785,178,923,619,000$2,418,740,733,002,562,000.00$13,607$553.09+$2418785178923.60MWPDPF
4$131,632,535,180,835,430,000,000$131,629,947,080,693,970,000,000.00$15,301$741.41+$131632535180835424.00MWPDPF
5$6,694,929,569,421,761,000,000,000,000$6,694,788,722,609,116,000,000,000,000.00$17,374$1,002.00+$6.69492956942176e+21MWPDPF
6$318,233,313,948,923,370,000,000,000,000,000$318,226,150,374,284,100,000,000,000,000,000.00$19,958$1,367.44+$3.1823331394892335e+26MWPDPF
7$14,137,160,116,927,522,000,000,000,000,000,000,000$14,136,819,607,281,600,000,000,000,000,000,000,000.00$23,243$1,887.87+$1.4137160116927522e+31MWPDPF
8$586,942,647,681,175,100,000,000,000,000,000,000,000,000$586,927,520,919,850,000,000,000,000,000,000,000,000,000.00$27,512$2,642.43+$5.8694264768117504e+35MWPDPF
9$22,774,359,015,829,920,000,000,000,000,000,000,000,000,000,000$22,773,730,987,196,898,000,000,000,000,000,000,000,000,000,000.00$33,197$3,759.22+$2.277435901582992e+40MWPDPF
10$825,873,857,526,507,000,000,000,000,000,000,000,000,000,000,000,000$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$40,973$5,451.69+$8.25873857526507e+44MWPDPF

WPDPF vs CL: Complete Analysis 2026

WPDPFStock

WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Full WPDPF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this WPDPF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WPDPF vs SCHDWPDPF vs JEPIWPDPF vs OWPDPF vs KOWPDPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.